

SpringerBriefs in Modern Perspectives on  
Disability Research

Gabriel Bennett



# Senotherapy

A Potential  
Pharmacological Strategy  
for Prolonging Human  
Lifespan and Healthspan

# **SpringerBriefs in Modern Perspectives on Disability Research**

## **Series Editors**

Gabriel Bennett, Independent Researcher, Klemzig, Australia

Emma Goodall, Healthy Possibilities, Seaford, Australia

This book series on disability research is a comprehensive collection of research on disability and related issues. The series is designed to promote interdisciplinary collaboration and exchange, bringing together scholars and practitioners from different fields to share their perspectives and insights. Disability research is an interdisciplinary field that examines the social, cultural, historical, and political dimensions of disability. It encompasses a wide range of topics, including disability rights, accessibility, assistive technologies, healthcare, education, employment, and social welfare. Disability research scholars employ a range of theoretical and methodological approaches to understand the experiences of people with disabilities, as well as the ways in which disability intersects with other social identities such as race, gender, sexuality, and class.

The series seeks to advance knowledge and understanding of disability by publishing rigorous, innovative, and relevant research. It aims to promote disability rights and social justice by highlighting the ways in which people with disabilities are marginalized and discriminated against in society, and advocating for greater social inclusion and accessibility. The series also seeks to inform policy and practice by disseminating research findings that can help to shape policy decisions and contribute to positive social change.

Gabriel Bennett

# Senotherapy

A Potential Pharmacological Strategy  
for Prolonging Human Lifespan  
and Healthspan

 Springer

Gabriel Bennett  
Independent Researcher  
Klemzig, SA, Australia

ISSN 3004-9709 ISSN 3004-9717 (electronic)  
SpringerBriefs in Modern Perspectives on Disability Research  
ISBN 978-981-97-3636-2 ISBN 978-981-97-3637-9 (eBook)  
<https://doi.org/10.1007/978-981-97-3637-9>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2024

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.  
The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

If disposing of this product, please recycle the paper.

# **Statement About the Usage of Artificial Intelligence**

ChatGPT, a large language model artificial intelligence program developed by the company OpenAI, was used to enhance the clarity of the concepts articulated in this book. All other procedures that were used to create this research were performed by Dr Gabriel Bennett.

# Contents

<b>1</b>	<b>Introduction to Senotherapies</b> . . . . .	1
1.1	Hallmarks of Biological Ageing . . . . .	1
1.2	Senescent Cells and Age-Associated Diseases . . . . .	3
1.2.1	Senescent Cell Accumulation . . . . .	3
1.2.2	Increased Amounts of SASPs Contribute to Senescent Cell Development . . . . .	3
1.3	Senotherapeutics: Treating Senescent Cells. . . . .	5
1.3.1	An Introduction to Senotherapeutics . . . . .	5
1.3.2	Senolytics . . . . .	7
1.3.3	Senomorphics. . . . .	7
1.4	Relevance of This Book to the <i>Modern Perspectives on Disability Research</i> SpringerBrief Series . . . . .	8
1.5	Intended Audience of This Book . . . . .	9
1.6	Pedagogical Features of This Book . . . . .	9
1.7	Description of Upcoming Chapters . . . . .	10
1.7.1	Chapter 2: The Accumulation of Senescent Cells and Disease . . . . .	10
1.7.2	Chapter 3: Current Research About Senotherapeutics. . . . .	10
1.7.3	Chapter 4: Final Comments . . . . .	10
	Further Reading . . . . .	10
<b>2</b>	<b>The Accumulation of Senescent Cells and Diseases</b> . . . . .	13
2.1	Causal Relationship Between Senescent Cell Accumulation and Age-Associated Diseases. . . . .	13
2.1.1	Type 2 Diabetes . . . . .	13
2.1.2	Type 1 Diabetes . . . . .	14
2.1.3	Idiopathic Pulmonary Fibrosis (IPF) . . . . .	15
2.1.4	Viral Infections. . . . .	15
2.1.5	Ophthalmic Diseases . . . . .	16
2.1.6	Multiple Sclerosis . . . . .	16
2.1.7	Parkinson's Disease . . . . .	17

2.1.8	Obesity-Related Diseases. . . . .	18
2.1.9	Non-alcoholic Fatty Liver Disease (NAFLD) . . . . .	18
2.1.10	Non-alcoholic Steatohepatitis (NASH) . . . . .	18
2.1.11	Periodontitis. . . . .	19
2.2	Conclusion . . . . .	19
	Further Reading . . . . .	19
<b>3</b>	<b>Current Research About Senotherapeutics</b> . . . . .	<b>21</b>
3.1	Senolytic Potential of Dasatinib and Quercetin (D + Q) . . . . .	21
3.1.1	Learning and Memory . . . . .	21
3.1.2	Reduced Adipose Tissue Inflammation and Improved Systemic Metabolic Function . . . . .	22
3.1.3	Muscle Wasting in Chronic Kidney Disease (CKD) . . . . .	22
3.1.4	Age-Dependent Intervertebral Disc Degeneration. . . . .	23
3.1.5	Non-alcoholic Fatty Liver Disease (NAFLD) . . . . .	23
3.1.6	Cardiovascular Diseases . . . . .	24
3.1.7	Obesity-Induced Metabolic Disorders . . . . .	24
3.2	Senomorphic Potential of Metformin . . . . .	25
3.3	Senomorphic Potential of Rapamycin . . . . .	28
3.4	Human Trials of Senotherapeutic Candidates . . . . .	29
3.5	Future Opportunities for Senotherapeutic Research . . . . .	31
3.5.1	Evaluating the Toxicity of Senotherapeutics . . . . .	31
3.5.2	Defining and Classifying Ageing as a Disease . . . . .	31
3.5.3	Performing More Studies About Treatment Regimen and Frequency. . . . .	32
3.5.4	Combining Senotherapies with Other Anti-Ageing Treatments . . . . .	32
3.5.5	Addressing the Heterogeneity of Senescent Cells . . . . .	32
3.5.6	Validating if Senotherapies Slow Ageing . . . . .	33
3.5.7	Preventing Senotherapies from Inhibiting the Therapeutic Benefits of Senescent Cells . . . . .	33
3.5.8	Examining the Long-Term Therapeutic Benefits of Senotherapies. . . . .	33
3.5.9	Conducting More Research About Senotherapeutics . . . . .	34
3.6	Conclusion . . . . .	36
	Further Reading . . . . .	36
<b>4</b>	<b>Final Comments</b> . . . . .	<b>41</b>
	References. . . . .	42
	<b>Appendices</b> . . . . .	<b>45</b>
	Appendix 1: History of the Discovery and Development of Metformin to Treat Diabetes . . . . .	45
	Appendix 2: Summary of Key Targets and Pathways Impacted by Metformin as Evidenced by Their Modulation in Cell Lines, <i>C. elegans</i> , <i>Drosophila</i> , and Rodents . . . . .	48



Appendix 3: Clinical Trials Using Metformin for Targeting Biological Ageing on <https://www.clinicaltrials.gov> as of February 18, 2024 . . . . . 51

Appendix 4: Characteristics of Studies Examining the Effects of Rapamycin and Its Derivatives on Healthy Individuals and Individuals with Age-Related Diseases. . . . . 59

Appendix 5: Clinical Trials of Senotherapeutics Registered on <https://www.clinicaltrials.gov> as of February 18, 2024 . . . . . 64

**Glossary** . . . . . 93

**References** . . . . . 95

## About the Author

**Gabriel Bennett, PhD** Dr. Gabriel Bennett, the pen name for Dr. Matthew Bennett, holds a PhD in Disability Studies from Flinders University, Australia. He has lectured in Disability Studies at Griffith University, Queensland. He has also advised the Australian Government's AutismCRC and has published articles for the *Journal of Autism and Developmental Disorders*. He is actively involved in supporting autistics and exploring key issues concerning disability. He has published several books, including:

Bennett, M., Webster, A. A., Goodall, E., & Rowland, S. (2019). *Life on the autism spectrum: Translating myths and misconceptions into positive futures*. Springer Nature. <https://doi.org/10.1007/978-981-13-3359-0>

Bennett, M., & Goodall, E. (2021). *Employment of persons with autism: A scoping review*. Springer Nature. <https://doi.org/10.1007/978-3-030-82174-6>

Bennett, M., & Goodall, E. (2022). *Addressing underserved populations in autism spectrum research: An intersectional approach*. Emerald Publishing Group. <https://doi.org/10.1108/9781803824635>

Bennett, G. (2023). *Autistic people in dental and medical clinics: Challenges and solutions*. Springer Nature. <https://doi.org/10.1007/978-981-99-2359-5>

# Abbreviations

CKD	Chronic kidney disease
D + Q	Dasatinib and quercetin
DEN	Diethylnitrosamine
HCC	Hepatocellular carcinoma
HFD	High fat diet
ICD-11	International Classification of Diseases 11th Revision
IPF	Idiopathic pulmonary fibrosis
LGBT	Lesbian, Gay, Bisexual, and Transgender
MILES	Metformin in longevity study
NAFLD	Non-alcoholic fatty liver disease
NASH	Non-alcoholic steatohepatitis
SASP	Senescence-associated secretory phenotype
TAME	Targeting Ageing with Metformin
WHO	World Health Organization